Non-pharmaceutical treatment combats recurring Clostridium Difficile infections
Transplanting human donor fecal microbiota into the colon of a patient infected with Clostridiodes difficile (C. diff) may be the best treatment for those not helped by C. diff targeted antibiotics, according to an article in the Journal of the American Osteopathic Association.
C. diff is the most common healthcare-acquired infection in the United States. It affects nearly half a million patients each year and becomes a recurring infection for nearly a third of them. If untreated, C. diff can lead to sepsis and death.
“Twenty five years ago C. diff infections were easier to manage and often resolved with discontinuation of the initiating antibiotic,” says Robert Orenstein, DO, an infectious disease specialist at Mayo Clinic and lead author on this article. “However, these infections have become increasingly common and pernicious.”
The standard and FDA-approved treatment for C. diff is a course of oral vancomycin, an antibiotic. However, even the medications used to eliminate C. diff can perpetuate the infection by killing off beneficial microbes. Newer antibiotics that more specifically target C. diff have been developed but they can be prohibitively expensive, according to Dr. Orenstein.
“Think of your gut as a forest and C. diff as a weed,” says Dr. Orenstein. “In a thriving forest, weeds barely get a foothold. But if you burn the forest down, the weeds are going to flourish.”
Unlike antibiotics, which are destructive by definition, fecal transplants or microbial replacement therapies, repopulate the gut with a diverse group of microbes that may block the C. diff‘s spore from germinating and propagating disease via its toxins. Transplants have several delivery methods, including enemas, capsules and direct instillation, to replace the diverse flora that maintain health and improve metabolism.
Currently, there are no FDA-approved fecal transplant products and performing fecal transplants is considered an investigational procedure. Dr. Orenstein notes there are several companies with products in Phase 3 clinical trials that could come to market as early as 2020. For this reason he strongly urges healthcare providers to refer patients with recurrent C. diff for these trials rather than for fecal transplants. In the meantime, the FDA reserves fecal transplants for patients who have experienced a second recurrence (third episode) of C. diff infection.
C. diff is common in healthcare settings and public spaces and rarely causes problems in people with healthy gut microbiota and immune systems, according to researchers. However, people who are already ill and taking antibiotics, chemotherapy, or proton pump inhibitors–which all greatly disrupt the gut ecosystem–are at risk. Elderly patients are especially vulnerable.
Dr. Orenstein expects the new treatment options will improve outcomes but says physicians need to assume greater responsibility for prevention.
“One of the most effective things physicians can do is become more responsible with antibiotic prescriptions,” says Dr. Orenstein. “That means only prescribing when they are clearly indicated, not for colds or viral sinus infections. We also must be especially judicious with elderly patients.”
The Latest on: Fecal transplants
via Google News
The Latest on: Fecal transplants
- Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunityon May 11, 2020 at 2:08 am
Sepsis due to multidrug resistant pathogens is the most common cause of death in intensive care units. Here, the authors report that fecal microbiota transplant (FMT) can rescue mice from lethal ...
- Real-world FMT seen as highly effective for C. diff treatmenton May 9, 2020 at 5:35 am
Results from a real-word study showed fecal microbiota transplantation for Clostridioides difficile infection was highly effective, with little serious adverse events related to the procedure, ...
- Individualized mosaics of microbial strains transfer from the maternal to the infant guton May 8, 2020 at 1:03 pm
Researchers have used a microbiome 'fingerprint' method to report that an individualized mosaic of microbial strains is transmitted to the infant gut microbiome from a mother giving birth through ...
- Seres Therapeutics: Clinical Data Coming Soonon May 6, 2020 at 7:49 am
Seres will have a data-rich 2020 with two late-stage readouts (SER-109 and SER-287) and a Phase 1 readout as well (SER-401). These readouts, if positive will mo ...
- Fecal transplant may benefit some patients with multidrug-resistant organismson May 5, 2020 at 9:13 am
Chronically ill patients infected with multidrug-resistant organisms (MDROs) during extensive medical care for serious conditions may benefit from fecal microbiota transplantation (FMT), a pilot study ...
- Fecal transplants may help combat obesity and diabetes: Know more about this new treatmenton May 5, 2020 at 5:46 am
Fecal transplants are currently used to treat gastrointestinal infections and other conditions.It uses stool of a healthy donor to treat sick person.
- Viruses gleaned from healthy feces fight obesity in miceon May 4, 2020 at 7:29 pm
Altering the gut microbiome by transplanting the stool contents from a healthy donor is emerging as a promising way to treat a variety of conditions, including everything from autism to inflammatory ...
- Viruses from stool can help fight obesity and type 2 diabeteson May 4, 2020 at 9:34 am
Obese mice with unhealthy lifestyles gain significantly less weight and avoid type 2 diabetes when they receive viruses transplanted from the stool of lean mice. These are the findings of a new ...
- Can transplanting poop viruses treat obesity and diabetes?on May 4, 2020 at 8:40 am
A fecal transplant of viruses shows promise in mice for treating obesity and type 2 diabetes, report researchers.
- FMT Tied to Health Improvements Beyond Infection Clearanceon April 30, 2020 at 1:06 pm
Case series found shorter hospital stays and fewer, more treatable infections with fecal microbiota transplant ...
via Bing News